References
- Elble RJ. Inhibition of forearm EMG by palatal myoclonus. Mov Disord. 1991;6:324–329.
- Deuschl G, Mischke G, Schenck E, et al. Symptomatic and essential rhythmic palatal myoclonus. Brain. 1990;113:1645–1672.
- Sinclair CF, Gurey LE, Blitzer A. Palatal myoclonus: algorithm for management with botulinum toxin based on clinical disease characteristics. Laryngoscope. 2014;124:1164–1169.
- Elziere M, Roman S, Nicollas R, et al. Objective tinnitus associated with essential palatal myoclonus: report in a child. Int Tinnitus J. 2007;13:157–158.
- Park SN. Objective Tinnitus. Hanyang Med Rev. 2016;36:99–108.
- Park SN, Bae SC, Lee GH, et al. Clinical characteristics and therapeutic response of objective tinnitus due to middle ear myoclonus: a large case series. Laryngoscope. 2013;123:2516–2520.
- Kim HJ, Lee HJ, An SY, et al. Analysis of the prevalence and associated risk factors of tinnitus in adults. PLoS One. 2015;10:e0127578.
- Yin S, Stucker FJ, Nathan CO. Clinical application of botulinum toxin in otolaryngology, head and neck practice. J La State Med Soc. 2001;153:92–97.
- Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuro Psiquiatr. 2005;63:180–185.
- Qaqish C. Botulinum Toxin Use in the Upper Face. Atlas Oral Maxillofac Surg Clin North Am. 2016;24:95–103.
- Levy A, Chen R. Myoclonus: Pathophysiology and Treatment Options. Curr Treat Options Neurol. 2016;18:21.
- Rothwell JC. 1994. Control of human voluntary movements. 2nd ed. London: Chapman & Hall.
- Gilio F, Currà A, Lorenzano C, et al. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol. 2000;48:20–26.